Division of Endocrinology and Diabetes and Bone Disease, Mount Sinai School of Medicine, One Gustave L. Levy Place, New York, NY 10029, USA.
Endocrinol Metab Clin North Am. 2011 Jun;40(2):409-17, ix. doi: 10.1016/j.ecl.2011.01.011.
Glucocorticoids remain a valuable and necessary component of therapy for many diseases. Nonetheless, sustained glucocorticoid treatment increases potential for future cardiovascular disease through multiple pathways, resulting in a tradeoff between benefit and harm. This article explores the potential mechanisms of glucocorticoid-induced hyperglycemia and dyslipidemia. Interactions between glucocorticoids and other potential cardiovascular risk factors are also reviewed. Safe, alternate strategies for minimizing the need for glucocorticoids are urgently needed.
糖皮质激素仍然是许多疾病治疗中非常有价值且必不可少的组成部分。尽管如此，持续的糖皮质激素治疗通过多种途径增加了未来发生心血管疾病的风险，从而在获益和危害之间产生了权衡。本文探讨了糖皮质激素引起的高血糖和血脂异常的潜在机制。还回顾了糖皮质激素与其他潜在心血管危险因素之间的相互作用。迫切需要安全的替代策略来最小化糖皮质激素的需求。
